Marina Lesina

Dr. Marina Lesina

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MLMarina Lesina
Marina Lesina
SWSonja Maria Wörmann
Sonja Maria Wörmann
JMJennifer P Morton
Jennifer P Morton
KDKalliope Diakopoulos
Kalliope Diakopoulos
OKOlga Korneeva
Olga Korneeva
HAHana Algül
Hana Algül
Tumor suppression that is mediated by oncogene-induced senescence (OIS) is considered to function as a safeguard during development of pancreatic ductal adenocarcinoma (PDAC). However, the mechanisms that regulate OIS in PDAC are poorly understood. Here, we have determined that nuclear RelA reinforces OIS to inhibit carcinogenesis in the Kras mouse model of PDAC. Inactivation of RelA accelerated pancreatic lesion formation in Kras mice by abrogating the senescence-associated secretory phenotype (SASP) gene transcription signature. Using genetic and pharmacological tools, we determined that RelA activation promotes OIS via elevation of the SASP factor CXCL1 (also known as KC), which activates CXCR2, during pancreatic carcinogenesis. In Kras mice, pancreas-specific inactivation of CXCR2 prevented OIS and was correlated with increased tumor proliferation and decreased survival. Moreover, reductions in CXCR2 levels were associated with advanced neoplastic lesions in tissue from human pancreatic specimens. Genetically disabling OIS in Kras mice caused RelA to promote tumor proliferation, suggesting a dual role for RelA signaling in pancreatic carcinogenesis. Taken together, our data suggest a pivotal role for RelA in regulating OIS in preneoplastic lesions and implicate the RelA/CXCL1/CXCR2 axis as an essential mechanism of tumor surveillance in PDAC.

1 May 2020 in Gastroenterology
Verified
Journal Article
Closed access
Atsushi MasamuneAtsushi Masamune
Atsushi Masamune
HKHiroshi Kotani
Hiroshi Kotani
FSFranziska Lena Sörgel
Franziska Lena Sörgel
Jian-Min ChenJian-Min Chen
Jian-Min Chen
SHShin Hamada
Shin Hamada
TSTooru Shimosegawa
Tooru Shimosegawa

1 January 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
KGKıvanç Görgülü
Kıvanç Görgülü
KDKalliope Diakopoulos
Kalliope Diakopoulos
JAJiaoyu Ai
Jiaoyu Ai
BSBenjamin Schoeps
Benjamin Schoeps
DKDerya Kabacaoglu
Derya Kabacaoglu
HAHana Algül
Hana Algül

24 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
KGKıvanç Görgülü
Kıvanç Görgülü
KDKalliope Diakopoulos
Kalliope Diakopoulos
EKEzgi Kaya-Aksoy
Ezgi Kaya-Aksoy
KCKatrin J. Ciecielski
Katrin J. Ciecielski
JAJiaoyu Ai
Jiaoyu Ai
HAHana Algül
Hana Algül
Pancreatic cancer is one of the deadliest cancer types urgently requiring effective therapeutic strategies. Autophagy occurs in several compartments of pancreatic cancer tissue including cancer cells, cancer associated fibroblasts, and immune cells where it can be subjected to a multitude of stimulatory and inhibitory signals fine-tuning its activity. Therefore, the effects of autophagy on pancreatic carcinogenesis and progression differ in a stage and context dependent manner. In the initiation stage autophagy hinders development of preneoplastic lesions; in the progression stage however, autophagy promotes tumor growth. This double-edged action of autophagy makes it a hard therapeutic target. Indeed, autophagy inhibitors have not yet shown survival improvements in clinical trials, indicating a need for better evaluation of existing results and smarter targeting techniques. Clearly, the role of autophagy in pancreatic cancer is complex and many aspects have to be considered when moving from the bench to the bedside.

1 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
XWXiaobo Wang
Xiaobo Wang
RIRouzanna Istvanffy
Rouzanna Istvanffy
LYLinhan Ye
Linhan Ye
STSteffen Teller
Steffen Teller
MLMelanie Laschinger
Melanie Laschinger
IDI.Ekin Demir
I.Ekin Demir
Solid cancers like pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer, frequently exploit nerves for rapid dissemination. This neural invasion (NI) is an independent prognostic factor in PDAC, but insufficiently modeled in genetically engineered mouse models (GEMM) of PDAC. Here, we systematically screened for human-like NI in Europe’s largest repository of GEMM of PDAC, comprising 295 different genotypes. This phenotype screen uncovered 2 GEMMs of PDAC with human-like NI, which are both characterized by pancreas-specific overexpression of transforming growth factor α (TGF-α) and conditional depletion of p53. Mechanistically, cancer-cell-derived TGF-α upregulated CCL2 secretion from sensory neurons, which induced hyperphosphorylation of the cytoskeletal protein paxillin via CCR4 on cancer cells. This activated the cancer migration machinery and filopodia formation toward neurons. Disrupting CCR4 or paxillin activity limited NI and dampened tumor size and tumor innervation. In human PDAC, phospho-paxillin and TGF-α–expression constituted strong prognostic factors. Therefore, we believe that the TGF-α-CCL2-CCR4-p-paxillin axis is a clinically actionable target for constraining NI and tumor progression in PDAC.

1 April 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
VTVolodymyr Tsvilovskyy
Volodymyr Tsvilovskyy
RORoger Ottenheijm
Roger Ottenheijm
UKUlrich Kriebs
Ulrich Kriebs
ASAline Schütz
Aline Schütz
KDKalliope Diakopoulos
Kalliope Diakopoulos
Marc FreichelMarc Freichel
Marc Freichel
Regulated exocytosis is initiated by increased Ca 2+ concentrations in close spatial proximity to secretory granules, which is effectively prevented when the cell is at rest. Here we showed that exocytosis of zymogen granules in acinar cells was driven by Ca 2+ directly released from acidic Ca 2+ stores including secretory granules through NAADP-activated two-pore channels (TPCs). We identified OCaR1 (encoded by Tmem63a ) as an organellar Ca 2+ regulator protein integral to the membrane of secretory granules that controlled Ca 2+ release via inhibition of TPC1 and TPC2 currents. Deletion of OCaR1 led to extensive Ca 2+ release from NAADP-responsive granules under basal conditions as well as upon stimulation of GPCR receptors. Moreover, OCaR1 deletion exacerbated the disease phenotype in murine models of severe and chronic pancreatitis. Our findings showed OCaR1 as a gatekeeper of Ca 2+ release that endows NAADP-sensitive secretory granules with an autoregulatory mechanism preventing uncontrolled exocytosis and pancreatic tissue damage.